Maxacalcitol.
Research-backed compound with potential health benefits. Slows down the rapid growth of skin cells that causes psoriasis. It's a powerful, targeted form of Vitamin D for a specific medical condition.
Reviewed March 2026
- Category
- Compound
What Maxacalcitol is, and what it does.
- Does it work
- This is a prescription topical medicine a doctor directs, not a supplement ingredient. People after nutritional vitamin D use cholecalciferol or calcifediol instead.
- How much to take
- Your doctor will tell you. It's typically applied as a thin layer to affected skin once or twice daily. Don't guess.
- Time to feel it
- Applied to skin under medical direction, visible change comes gradually across weeks. What gets checked during use is serum calcium and phosphate, not a sensation.
- The first dose
- Nothing. Topical treatments for psoriasis work slowly. You won't see any changes for at least a week, maybe longer.
- With regular use
- With consistent use over weeks to months, it can significantly reduce psoriasis symptoms. Requires ongoing medical supervision to manage.
- How well tolerated
- Well tolerated when used as directed by a physician. The main risk is local skin irritation. Systemic absorption is rare but can be serious, which is why it's prescription-only.
- How it feels
- Like applying a non-greasy cream. The effect is a gradual, visual improvement in your skin's condition, not a sensation you feel.
- The overlooked benefit
- Swapping one carbon for an oxygen drops its grip on vitamin D binding protein, so it clears the blood fast. That short circulating life is the design, not a flaw.
5 to 10mcg a day is where Maxacalcitol works.
Source: Prescription vitamin D analog; Saito et al., Am J Nephrol 1998
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Maxacalcitol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- vitamin D receptor activation without needing liver or kidney hydroxylationNarrative review
- parathyroid hormone gene transcriptionRandomised trial
- skin cell turnover in topical useRandomised trial
- serum calcium and phosphate handlingRandomised trial
- faster plasma clearance than calcitriolNarrative review
Questions people ask about Maxacalcitol.
- Is this the same as Vitamin D pills?
- No. It's a potent synthetic version designed for topical use. It's much stronger and more targeted for skin than oral Vitamin D.
- Can I buy this over-the-counter?
- No. This is a prescription medication. Anything sold without a prescription is likely illegal, counterfeit, and unsafe.
- Will it help my mood or bones like regular Vitamin D?
- Unlikely. It's designed to act on skin cells with minimal absorption into the bloodstream. Stick to Vitamin D3 supplements for systemic benefits.
- What are the common side effects?
- Skin irritation where you apply it is the most common one. Things like itching, redness, or a slight burning sensation.
- Can I use it on my face?
- Ask your doctor first. Skin on the face is more sensitive, and they might recommend against it or suggest a specific application method.
- Why not just use a regular Vitamin D cream?
- This molecule is specifically engineered to be more effective on psoriasis skin cells while being less likely to cause side effects in the rest of the body.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Vitamin D receptor activation increases intestinal calcium absorption by inducing the transport proteins in the gut wall. Adding a calcium supplement pushes serum calcium in the same direction, so the two effects stack.
Carbonate salts deliver a large elemental calcium load that is absorbed more readily once the vitamin D receptor is activated. The rise in serum calcium from each adds to the other.
Cholecalciferol is hydroxylated to calcitriol, which activates the same vitamin D receptor maxacalcitol binds. Running both means one receptor pathway is being driven from two sources.
Calcifediol is the circulating precursor converted to the active hormone that occupies the vitamin D receptor. Its downstream signal overlaps entirely with an analogue acting at the same receptor.
Ergocalciferol raises circulating vitamin D metabolites that reach the same receptor. Its effect on calcium and phosphate handling runs in parallel with an analogue.
The hydroxylase enzymes that activate and inactivate vitamin D metabolites, and the vitamin D binding protein itself, depend on magnesium. Magnesium status shapes how the receptor pathway behaves.
Vitamin D receptor activation induces osteocalcin and matrix Gla protein, which only become functional after vitamin K dependent carboxylation. Without K2 the newly made proteins stay uncarboxylated.
Vitamin D receptor activation raises intestinal phosphate uptake alongside calcium. A phosphate load taken at the same time moves serum phosphate in the same direction.
The vitamin D receptor works as a heterodimer with the retinoid X receptor. High retinoid intake competes for that shared partner and can change how strongly vitamin D response elements are read.
Vitamin D receptor agonism raises intestinal calcium absorption and induces osteocalcin and matrix Gla protein transcription, but both of those proteins are inert until vitamin K dependent gamma-carboxylation activates them. Vitamin K status therefore determines whether newly transcribed Gla proteins can bind calcium at all. The relationship is textbook and does not depend on a combination trial.
Boron has been reported to affect circulating vitamin D metabolite levels and mineral handling in human nutritional studies, though the mechanism is not settled. Any relevance to a synthetic receptor agonist is indirect, since maxacalcitol does not require hydroxylation activation. Read this as speculative rather than established.
Magnesium is a required cofactor for the 25- and 1-alpha-hydroxylases and for the adenylate cyclase signalling that parathyroid hormone uses. Maxacalcitol bypasses the hydroxylation steps, since it arrives already 1,25-configured, but the downstream mineral-handling axis it acts on remains magnesium dependent. The cofactor relationship is settled biochemistry.
The vitamin D receptor binds DNA through two zinc-finger motifs, each coordinating a zinc ion. Without zinc the receptor cannot engage vitamin D response elements regardless of which agonist occupies the ligand pocket. This applies to maxacalcitol exactly as it does to calcitriol.
Strontium is absorbed through the same calcium transport routes and substitutes for calcium in bone mineral. A vitamin D receptor agonist that raises intestinal calcium transporter expression will raise strontium uptake alongside calcium. Strontium also confounds bone density measurement because of its higher atomic number.
Fermentation of inulin lowers colonic pH and raises the soluble ionised calcium fraction, increasing passive absorption independently of the vitamin D dependent transcellular route. A vitamin D receptor agonist acts on the transcellular route in the small intestine. The two mechanisms add rather than overlap, which matters when total calcium load is the thing being managed.
Activated charcoal adsorbs lipophilic molecules indiscriminately, and secosteroids are lipophilic. Any orally presented vitamin D analogue taken close to charcoal will be partly bound and not absorbed. Separation in time is the standard handling of this class of interaction.
Bentonite binds cations and organic molecules in the gut lumen through its layered aluminosilicate structure, which reduces the absorbed fraction of minerals and lipophilic actives taken alongside it. The effect is nonspecific and dose dependent. It applies to calcium as much as to the analogue itself.
Psyllium forms a viscous gel that slows lipid micelle formation and reduces the absorbed fraction of fat-soluble compounds taken at the same time. Vitamin D and its analogues absorb by that lipid route. The practical response is timing separation rather than dose change.
Phytate binds calcium, magnesium and zinc in the gut lumen and blocks their absorption; phytase hydrolyses phytate and releases those minerals. Vitamin D receptor agonism raises the transport capacity for calcium but cannot act on calcium that is already chelated. The two mechanisms operate at different points in the same sequence.
Nothing specific on file for Maxacalcitol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Maxacalcitol actually does.
Maxacalcitol is 22-oxacalcitriol: the carbon at position 22 of the calcitriol side chain is replaced by an oxygen atom, converting that part of the side chain into an ether linkage.
The 22-oxa substitution sharply lowers affinity for vitamin D binding protein, so the analogue is cleared from plasma far faster than calcitriol while retaining vitamin D receptor binding.
Ligand-bound vitamin D receptor heterodimerises with retinoid X receptor and binds vitamin D response elements in target gene promoters, which is the transcriptional route shared by every agonist of this class.
Maxacalcitol arrives already hydroxylated at both the 1-alpha and 25 positions, so it does not require hepatic or renal hydroxylation to become receptor-active, unlike cholecalciferol or calcifediol.
Where Maxacalcitol comes from.
This is a laboratory-made cousin of active vitamin D, not something extracted from anything. Chemists swap one carbon in the tail of the molecule for an oxygen, install both of the hydroxyl groups the body would normally add, then purify hard to remove the wrong-shaped versions. It is a prescription drug, made to drug standards.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Production starts from vitamin D related secosteroid building blocks prepared by total or semi-synthesis, not from any plant, animal or microbial extract.
The defining step replaces the carbon at position 22 with an oxygen, building an ether linkage into the side chain. That single substitution is what distinguishes the molecule from calcitriol.
Both hydroxyl groups required for receptor binding are installed chemically during synthesis, so the finished molecule needs no metabolic activation in the body.
Secosteroid synthesis produces stereoisomers and geometric isomers that have to be separated, since the wrong isomer is not receptor-active. Purity specifications for this class are pharmaceutical grade.
Formulated either as a sterile aqueous injection with solubilising excipients or dispersed into a topical ointment base, then packed under light protection because secosteroids are photolabile.
Specific route details are manufacturer proprietary and are not published in a form that can be described step by step here.
The forms it comes in.
The studies, linked.
4 sources behind our Maxacalcitol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialComparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismClinicalTrials.gov ↗PHASE3 · 255 participants · Completed
- Clinical trialLate Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)ClinicalTrials.gov ↗PHASE2 · 153 participants · Completed
- Clinical trialPhase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismClinicalTrials.gov ↗PHASE2 · 47 participants · Completed
- Clinical trialA Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary HyperparathyroidismClinicalTrials.gov ↗NA · 35 participants · Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 621 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Maxacalcitol is, not how risky it is. A report is not proof Maxacalcitol caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.